Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
Authors:
Open Access
- 21 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e59735
Abstract
The characteristic neuropathological changes associated with Alzheimer’s disease (AD) and other lines of evidence support the amyloid cascade hypothesis. Viewing amyloid deposits as the prime instigator of dementia has now led to clinical trials of multiple strategies to remove or prevent their formation. We performed neuropathological and biochemical assessments of 3 subjects treated with bapineuzumab infusions. Histological analyses were conducted to quantify amyloid plaque densities, Braak stages and the extent of cerebral amyloid angiopathy (CAA). Amyloid-β (Aβ) species in frontal and temporal lobe samples were quantified by ELISA. Western blots of amyloid-β precursor protein (AβPP) and its C-terminal (CT) fragments as well as tau species were performed. Bapineuzumab-treated (Bapi-AD) subjects were compared to non-immunized age-matched subjects with AD (NI-AD) and non-demented control (NDC) cases. Our study revealed that Bapi-AD subjects exhibited overall amyloid plaque densities similar to those of NI-AD cases. In addition, CAA was moderate to severe in NI-AD and Bapi-AD patients. Although histologically-demonstrable leptomeningeal, cerebrovascular and neuroparenchymal-amyloid densities all appeared unaffected by treatment, Aβ peptide profiles were significantly altered in Bapi-AD subjects. There was a trend for reduction in total Aβ42 levels as well as an increase in Aβ40 which led to a corresponding significant decrease in Aβ42:Aβ40 ratio in comparison to NI-AD subjects. There were no differences in the levels of AβPP, CT99 and CT83 or tau species between Bapi-AD and NI-AD subjects. The remarkable alteration in Aβ profiles reveals a dynamic amyloid production in which removal and depositional processes were apparently perturbed by bapineuzumab therapy. Despite the alteration in biochemical composition, all 3 immunized subjects exhibited continued cognitive decline.Keywords
This publication has 98 references indexed in Scilit:
- Single-Molecule Atomic Force Microscopy Force Spectroscopy Study of Aβ-40 InteractionsBiochemistry, 2011
- Stoichiometry and Affinity of the Human Serum Albumin-Alzheimer's Aβ Peptide InteractionsBiophysical Journal, 2011
- Blood–brain barrier breakdown as a therapeutic target in traumatic brain injuryNature Reviews Neurology, 2010
- Fibrinogen and β-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's DiseaseNeuron, 2010
- Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's DiseaseMount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2010
- The Role of Metabolic Disorders in Alzheimer Disease and Vascular DementiaArchives of Neurology, 2009
- The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007Cell and Tissue Banking, 2008
- Amyloid-β vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloidNeuroscience, 2007
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991